OncoMatch/Clinical Trials/NCT06303713
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Is NCT06303713 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Carboplatin and 177Lu-PSMA-617 for prostate cancer.
Treatment: Carboplatin · 177Lu-PSMA-617 — The purpose of this study is to see whether the combination of a chemotherapy drug, carboplatin, along with the radioligand treatment, 177Lu-PSMA-617, is safe in treating prostate cancer and whether the combination is effective in shrinking or preventing growth of prostate cancer. The names of the study drugs used in this research study are: * Carboplatin (A type of chemotherapy) * 177Lu-PSMA-617 (A type of radioligand therapy)
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Required: FOLH1 PSMA-avid lesion (with uptake > liver) on 68GaPSMA-11 PSMA-PET (uptake > liver)
Presence of ≥1 PSMA-avid lesion (with uptake > liver) on baseline/screening 68GaPSMA-11 PSMA-PET.
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: taxane (docetaxel, cabazitaxel) — localized, recurrent or metastatic
Prior receipt of at least one taxane chemotherapy (docetaxel or cabazitaxel)
Must have received: androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, darolutamide) — localized, recurrent or metastatic
at least one ARPI (abiraterone, enzalutamide, apalutamide or darolutamide)
Cannot have received: radioligand therapy (177Lu-PSMA-617)
Participants who have previously received 177Lu-PSMA-617.
Lab requirements
Blood counts
anc ≥1.5×10^9/l; platelets ≥100×10^9/l; hemoglobin ≥9g/dl (≥90g/l), independent of transfusions
Kidney function
egfr ≥30 ml/min/1.73 m2 (based on cockcroft-gault formula or 24 hour urine collection)
Liver function
total bilirubin ≤1.5 × uln or <2 × uln if known or suspected gilbert's syndrome; alt and ast ≤3 × uln or ≤5 × uln if liver metastases present
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify